fbpx Hexokinase-I protection against apoptotic cell death is14 mediated via interaction with the Voltage Dependent Anion Channel-1: mapping the site of binding |ARAB AMERICAN UNIVERSITY
Contact information for Technical Support and Student Assistance ... Click here

Hexokinase-I protection against apoptotic cell death is14 mediated via interaction with the Voltage Dependent Anion Channel-1: mapping the site of binding

Authors: 
Abu- Hamad S.
Zaid H.
Israelson A.
Nahon E.
ShoshanBarmatz V.
Journal Name: 
Journal of Biological Chemistry
Volume: 
283
Issue: 
19
Pages From: 
13482
To: 
13490
Date: 
Friday, May 9, 2008
Abstract: 
In brain and tumor cells, the hexokinase isoforms HK-I and HK-II bind to the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane. We have previously shown that HK-I decreases murine VDAC1 (mVDAC1) channel conductance, inhibits cytochrome c release, and protects against apoptotic cell death. Now, we define mVDAC1 residues, found in two cytoplasmic domains, involved in the interaction with HK-I. Protection against cell death by HK-I, as induced by overexpression of native or mutated mVDAC1, served to identify the mVDAC1 amino acids required for interaction with HK-I. HK-I binding to mVDAC1 either in isolated mitochondria or reconstituted in a bilayer was inhibited upon mutation of specific VDAC1 residues. HK-I anti-apoptotic activity was also diminished upon mutation of these amino acids. HK-I-mediated inhibition of cytochrome c release induced by staurosporine was also diminished in cells expressing VDAC1 mutants. Our results thus offer new insights into the mechanism by which HK-I promotes tumor cell survival via inhibition of cytochrome c release through HK-I binding to VDAC1. These results, moreover, point to VDAC1 as a key player in mitochondrially mediated apoptosis and implicate an HK-I-VDAC1 interaction in the regulation of apoptosis. Finally, these findings suggest that interference with the binding of HK-I to mitochondria by VDAC1-derived peptides may offer a novel strategy by which to potentiate the efficacy of conventional chemotherapeutic agents.